New spesolimab data show promising results in patients with generalised pustular psoriasis flares
Clinical improvements were consistent across patient subgroups including age, gender, ethnicity, and IL-36 gene mutation status
Clinical improvements were consistent across patient subgroups including age, gender, ethnicity, and IL-36 gene mutation status
There are currently no approved systemic treatments for prurigo nodularis; regulatory filings for prurigo nodularis planned in the first half of 2022
The enhanced portfolio includes the Scenaria View, Supria series, The Echelon Smart and Arietta series
Titan 2 pivotal study to evaluate implantable tibial neuromodulation (TNM) device to help expand patient access to advanced therapy
The accelerated use of technology in clinical trials and the shift towards virtual trials is here to stay
#BeTheChangeForTB is a public awareness initiative under the Corporate TB Pledge and aims to create a cadre of Youth Changemakers who can act as catalysts of change to help eliminate TB from India
The FDA decision is primarily informed by the positive results of a proof-of-concept, Phase 2a study evaluating the safety, immunogenicity, and efficacy of a single dose of 120µg RSVpreF in a human viral challenge model in healthy adults 18 to 50 years of age
It is a point-of-care portable, battery-operated, IoT-enabled platform with a sample to result in less than 1 hour
First approved in 2019, Rinvoq is a JAK inhibitor approved for four indications across gastroenterology, dermatology and rheumatology
Clinical surveillance solution is designed to identify emergent patient deterioration and offer enhanced patient data visibility, flexible viewing options, and clinical decision support
Subscribe To Our Newsletter & Stay Updated